The following quote was from the paper below that commented on FTO inhibitors in general. How do you think Zantrene stacks up in these areas?
"few of the currently developed small-molecule FTO inhibitors are available for clinical applications due to mild bioavailability, low sensitivity, and/or poor selectivity."
https://www.mdpi.com/1422-0067/23/10/5815/pdf?version=1653299772
General Comments / Chat, page-5699
-
- There are more pages in this discussion • 5,604 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
|
|||||
Last
$1.56 |
Change
0.010(0.65%) |
Mkt cap ! $264.0M |
Open | High | Low | Value | Volume |
$1.55 | $1.56 | $1.51 | $95.69K | 62.25K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 3015 | $1.55 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.56 | 4018 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 2000 | 1.560 |
2 | 3015 | 1.550 |
2 | 17973 | 1.530 |
1 | 19190 | 1.525 |
1 | 20000 | 1.520 |
Price($) | Vol. | No. |
---|---|---|
1.505 | 50 | 1 |
1.560 | 4024 | 1 |
1.570 | 4602 | 2 |
1.580 | 15715 | 3 |
1.600 | 2319 | 1 |
Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online